Literature DB >> 30250619

Survivin expression modulates the sensitivity of A549 lung cancer cells resistance to vincristine.

Chengwei Zhou1, Yonggang Zhu1, Bin Lu1, Weijun Zhao1, Xiaodong Zhao1.   

Abstract

Lung cancer is the leading cause of cancer-associated mortalities worldwide. Chemotherapeutic drug vincristine is widely used to treat lung cancer; however, the acquisition of drug resistance is the major limitation of chemotherapy, and it is thus important to determine the mechanism underlying vincristine resistance in lung cancer. Survivin has been reported to be associated with the development of drug resistance and be involved in the progression of non-small cell lung cancer. In the present study, a vincristine-resistant lung cancer cell line, A549/VCR, was used to investigate the possible involvement of survivin in the acquisition of vincristine resistance. Western blot analysis demonstrated that survivin protein expression level was markedly higher in A549/VCR cells compared with in control A549 cells, whereas p53 expression level was lower in A549/VCR cells compared with in A549 cells. Thus, wild-type p53 was overexpressed in A549/VCR cells and it reversed vincristine resistance of A549/VCR cells via the inhibition of survivin expression. Furthermore, survivin was knocked down by small interfering RNA technology and the effects on viability and apoptosis of resistant cells were investigated. MTT, Annexin V-fluorescein isothiocyanate/propidium iodide and caspase-3 activity assays indicated that survivin silencing significantly inhibited cell viability and enhanced apoptosis induced by vincristine treatment in A549/VCR cells compared with non-silenced A549/VCR cells. These results suggested that survivin expression regulated by p53 may serve an important role in drug resistance in A549/VCR cells and may be a potential target for enhancing vincristine sensitivity in A549 lung cancer cells. Additionally, the present study revealed that A549/VCR cells exhibited cross resistance to methotrexate (MTX) and survivin silencing re-sensitized A549/VCR cells to MTX, indicating the crucial role of survivin in regulating A549 cells sensitivity to anticancer drugs. The results of the present study are significant for determining the underlying mechanism of vincristine resistance in lung cancer.

Entities:  

Keywords:  apoptosis; drug resistance; p53; survivin; viability; vincristine

Year:  2018        PMID: 30250619      PMCID: PMC6144891          DOI: 10.3892/ol.2018.9277

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  34 in total

Review 1.  Structural, functional and therapeutic biology of survivin.

Authors:  N K Sah; Z Khan; G J Khan; P S Bisen
Journal:  Cancer Lett       Date:  2006-04-18       Impact factor: 8.679

Review 2.  The paradigm of mutant p53-expressing cancer stem cells and drug resistance.

Authors:  Yoav Shetzer; Hilla Solomon; Gabriela Koifman; Alina Molchadsky; Stav Horesh; Varda Rotter
Journal:  Carcinogenesis       Date:  2014-03-21       Impact factor: 4.944

3.  Survivin expression in pre-invasive lesions and non-small cell lung carcinoma.

Authors:  Nalan Akyürek; Leyla Memiş; Ozgür Ekinci; Nurdan Köktürk; Can Oztürk
Journal:  Virchows Arch       Date:  2006-06-30       Impact factor: 4.064

Review 4.  Assessing TP53 status in human tumours to evaluate clinical outcome.

Authors:  T Soussi; C Béroud
Journal:  Nat Rev Cancer       Date:  2001-12       Impact factor: 60.716

Review 5.  Mechanism of action of antitumor drugs that interact with microtubules and tubulin.

Authors:  M A Jordan
Journal:  Curr Med Chem Anticancer Agents       Date:  2002-01

6.  A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy.

Authors:  R A Olie; A P Simões-Wüst; B Baumann; S H Leech; D Fabbro; R A Stahel; U Zangemeister-Wittke
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

7.  "Super p53" mice exhibit enhanced DNA damage response, are tumor resistant and age normally.

Authors:  Isabel García-Cao; Marta García-Cao; Juan Martín-Caballero; Luis M Criado; Peter Klatt; Juana M Flores; Jean-Claude Weill; María A Blasco; Manuel Serrano
Journal:  EMBO J       Date:  2002-11-15       Impact factor: 11.598

Review 8.  Topoisomerase degradation, DSB repair, p53 and IAPs in cancer cell resistance to camptothecin-like topoisomerase I inhibitors.

Authors:  Maja T Tomicic; Bernd Kaina
Journal:  Biochim Biophys Acta       Date:  2012-09-21

9.  The role of cytochrome c oxidase subunit Va in non-small cell lung carcinoma cells: association with migration, invasion and prediction of distant metastasis.

Authors:  Wen-Liang Chen; Kuang-Tai Kuo; Teh-Ying Chou; Chien-Lung Chen; Chih-Hao Wang; Yau-Huei Wei; Liang-Shun Wang
Journal:  BMC Cancer       Date:  2012-06-29       Impact factor: 4.430

Review 10.  Magnetic resonance imaging for N staging in non-small cell lung cancer: A systematic review and meta-analysis.

Authors:  Yuanyuan Zhang; Qin Qin; Baosheng Li; Juan Wang; Kun Zhang
Journal:  Thorac Cancer       Date:  2015-01-08       Impact factor: 3.500

View more
  8 in total

1.  Suppression of Chromosome Instability Limits Acquired Drug Resistance.

Authors:  Elizabeth A Crowley; Nicole M Hermance; Conor P Herlihy; Amity L Manning
Journal:  Mol Cancer Ther       Date:  2022-10-07       Impact factor: 6.009

2.  Prognostic Value of BIRC5 in Lung Adenocarcinoma Lacking EGFR, KRAS, and ALK Mutations by Integrated Bioinformatics Analysis.

Authors:  Yajuan Cao; Weikang Zhu; Wanqing Chen; Jianchun Wu; Guozhen Hou; Yan Li
Journal:  Dis Markers       Date:  2019-04-09       Impact factor: 3.434

3.  Long Non-coding RNA LINC00628 Interacts Epigenetically with the LAMA3 Promoter and Contributes to Lung Adenocarcinoma.

Authors:  Shu-Feng Xu; Yue Zheng; Ling Zhang; Ping Wang; Chun-Mi Niu; Tong Wu; Qi Tian; Xiao-Bo Yin; Shan-Shan Shi; Lei Zheng; Li-Ming Gao
Journal:  Mol Ther Nucleic Acids       Date:  2019-08-14       Impact factor: 8.886

4.  Synthesis, In Silico Prediction and In Vitro Evaluation of Antitumor Activities of Novel Pyrido[2,3-d]pyrimidine, Xanthine and Lumazine Derivatives.

Authors:  Samar El-Kalyoubi; Fatimah Agili
Journal:  Molecules       Date:  2020-11-09       Impact factor: 4.411

5.  Identification and validation of an autophagy-related long non-coding RNA signature as a prognostic biomarker for patients with lung adenocarcinoma.

Authors:  Aimin Jiang; Na Liu; Shuheng Bai; Jingjing Wang; Huan Gao; Xiaoqiang Zheng; Xiao Fu; Mengdi Ren; Xiaoni Zhang; Tao Tian; Zhiping Ruan; Xuan Liang; Yu Yao
Journal:  J Thorac Dis       Date:  2021-02       Impact factor: 2.895

6.  Network Pharmacology Integrated Molecular Docking to Explore the Mechanism of Blister Beetle Therapy for Lung Adenocarcinoma.

Authors:  Shoujun Deng; Ying Mao; Heng Li; Gaofeng Li
Journal:  Contrast Media Mol Imaging       Date:  2022-07-14       Impact factor: 3.009

7.  Targeted non AR mediated smart delivery of abiraterone to the prostate cancer.

Authors:  Abu Baker; Mohammad Khalid; Imran Uddin; Mohd Sajid Khan
Journal:  PLoS One       Date:  2022-08-26       Impact factor: 3.752

8.  Selective Disruption of Survivin's Protein-Protein Interactions: A Supramolecular Approach Based on Guanidiniocarbonylpyrrole.

Authors:  Dennis Aschmann; Cecilia Vallet; Sunil K Tripathi; Yasser B Ruiz-Blanco; Max Brabender; Carsten Schmuck; Elsa Sanchez-Garcia; Shirley K Knauer; Michael Giese
Journal:  Chembiochem       Date:  2022-01-18       Impact factor: 3.461

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.